Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Insmed Incorporated (INSM)

17.4   -0.02 (-0.11%) 03-20 09:45
Open: 17.27 Pre. Close: 17.42
High: 17.54 Low: 17.29
Volume: 13,948 Market Cap: 2,373(M)

Technical analysis

as of: 2023-03-20 9:17:13 AM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 22.76     One year: 24.71
Support: Support1: 16.79    Support2: 13.97
Resistance: Resistance1: 19.49    Resistance2: 21.15
Pivot: 19.17
Moving Average: MA(5): 17.87     MA(20): 19.49
MA(100): 19.35     MA(250): 21.17
MACD: MACD(12,26): -0.7     Signal(9): -0.5
Stochastic oscillator: %K(14,3): 9.3     %D(3): 11.7
RSI: RSI(14): 30.5
52-week: High: 28.94  Low: 16.4
Average Vol(K): 3-Month: 1,305 (K)  10-Days: 1,316 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ INSM ] has closed above bottom band by 11.3%. Bollinger Bands are 42.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 17.54 - 17.66 17.66 - 17.75
Low: 16.48 - 16.65 16.65 - 16.77
Close: 17.19 - 17.42 17.42 - 17.59

Company Description

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.

Headline News

Sun, 19 Mar 2023
Peregrine Capital Management LLC Trims Holdings in Insmed ... - MarketBeat

Sat, 11 Mar 2023
Moore Capital Management LP purchases new Insmed Incorporated ... - Best Stocks

Fri, 10 Mar 2023
Insmed Incorporated (NASDAQ:INSM) Position Raised by Castleark ... - MarketBeat

Fri, 03 Mar 2023
Insmed Reports Inducement Grants Under NASDAQ Listing Rule ... - Galveston County Daily News

Mon, 27 Feb 2023
Insmed Incorporated (NASDAQ:INSM) to Report Earnings of ($1.03 ... - Best Stocks

Thu, 23 Feb 2023
Insmed Reports Fourth Quarter and Full Year 2022 Financial ... - PR Newswire

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 136 (M)
Shares Float 135 (M)
% Held by Insiders 1.4 (%)
% Held by Institutions 107.6 (%)
Shares Short 10,420 (K)
Shares Short P.Month 11,420 (K)

Stock Financials

EPS -3.73
EPS Est Next Qtl -0.67
EPS Est This Year -2.71
EPS Est Next Year -2.28
Book Value (p.s.) 0.64
Profit Margin (%) -196.3
Operating Margin (%) -194.9
Return on Assets (ttm) -20.7
Return on Equity (ttm) -193.3
Qtrly Rev. Growth 5.6
Gross Profit (p.s.) 1.39
Sales Per Share 1.79
EBITDA (p.s.) -3.46
Qtrly Earnings Growth 0
Operating Cash Flow -400 (M)
Levered Free Cash Flow -198 (M)

Stock Valuations

PE Ratio -4.69
PEG Ratio 0
Price to Book value 26.8
Price to Sales 9.68
Price to Cash Flow -5.94

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.